TORRENT PHARMACEUTICALS L DCF Valuation
TORNTPHARM · Healthcare · Current price ₹4,558.9
TORRENT PHARMACEUTICALS L cash-flow valuation
Our engine did not use a discounted-cash-flow model for TORRENT PHARMACEUTICALS L. It routes each business to the methods that suit it, and a DCF is a poor lens where cash-flow forecasts are fragile or the business is capital-structure driven. The methods it did use, and why, are set out below. Our published estimate is ₹4,778.
Try your own assumptions
Prefer to build the discounted cash flow yourself? The DCF calculator below opens pre-filled with TORRENT PHARMACEUTICALS L's reported free cash flow, net debt and share count, so you can set your own growth and discount rate.
How we got this fair value
Every number below is part of the same estimate for TORRENT PHARMACEUTICALS L. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹4,300 – ₹5,255
Why this method for this business
Relative P/E and EV/EBITDA are the most appropriate models for a pharmaceutical company like Torrent Pharmaceuticals, which has a durable moat and stable cash flows. These models align with the company's asset-light structure and its ability to generate consistent earnings.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
required inputs missing
- dcf: Not suitable for a pharmaceutical company with high capital intensity and uncertain future cash flows
- relative_pe: Already included in the model keys
What was missing
- Lack of forward-looking analyst estimates for EV/EBITDA model
- Limited data on capital allocation and financial strength
What drives it
15 inputs, grouped by how strong each claim is
- Sector-median P/E
- 72.03×
- Peers used
- 3
- EPS (TTM)
- 63.7 ₹/share
- Own-history median P/E
- 65.12×
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- Term: quality
- +1.8%
- Term: growth
- +14.2%
- Term: capital_allocation
- +13.5%
- Term: financial_strength
- -1.6%
- Term: history
- -2.9%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
quality 59/100 (about average) → neutral
durable ~12% CAGR (ROCE 19% > hurdle) → premium
capital allocation: rising ROCE funded by strong FCF → premium
financial strength: high leverage (D/E 1.7) → discount
history: market paid -10% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- +4.1%
- Fair-multiple confidence
- 74%
- Fair P/E
- 75×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for TORRENT PHARMACEUTICALS L: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on TORRENT PHARMACEUTICALS L
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.